BioSpace News Archive

OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the following upcoming investor conferences:

Radiko Holdings (CSE:RDKO) (the “Company”) reports that it intends to rely upon the extension provided by the Canadian Securities Administrators (“CSA”) relating to is interim financial statements, accompanying management discussion and analysis and related CEO and CFO certifications for the period ended June 30, 2020 (the “Q2 Interim Filings”)

Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials

Odonate Therapeutics, Inc. announced the pricing of an underwritten public offering of 5,614,036 shares of its common stock, offered at a price of $14.25 per share.

Afya Limited (Nasdaq: AFYA) (“Afya” or the “Company”), the leading medical education group in Brazil, today reported financial and operating results for the three and six-month periods ended June 30, 2020 (second quarter 2020, 2Q20 and first half 2020, respectively

Ascentage Pharma announced that preclinical study results of the company’s novel inhibitor of apoptosis proteins antagonist APG-1387 in the treatment of CHB infection have been presented in an oral presentation at the Digital International Liver Congress™ 2020 held by the European Association for the Study of the Liver.

ViewRay, the GenesisCare Foundation and the Pancreatic Cancer Research Fund Work Together to Provide MRIdian Radiation Therapy at No Cost to NHS Pancreatic Cancer Patients

Oncologie, Inc., a precision medicine company using an innovative RNA-based biomarker platform to develop novel, targeted oncology therapies, announced that Laura Benjamin, Ph.D., Founder and CEO of Oncologie, will participate at the 18th Annual Morgan Stanley Global Healthcare Conference taking place virtually during September 14-18, 2020.

Zomedica Pharmaceuticals Corp. announced that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders.

Kaleido Biosciences, Inc. announced that data from Microbiome Metabolic Therapy candidate KB174 for hepatic encephalopathy will be featured during The Digital International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver.